Research programme: non-small cell lung cancer therapeutics - Jenthera Therapeutics
Latest Information Update: 30 Aug 2023
At a glance
- Originator Jenthera Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action KRAS protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Non-small cell lung cancer
Most Recent Events
- 13 Jul 2023 Research programme: non-small cell lung cancer therapeutics - Jenthera Therapeutics is available for licensing as of 13 Jul 2023. https://www.jenthera.com/programs
- 13 Jul 2023 Early research in Non-small cell lung cancer in Canada (IV) (Jenthera Therapeutics pipeline, July 2023)